MAPT and Alzheimer disease: Significant alterations in the AD brain extend well beyond Aβ and tau pathology, with disruptions in the serotonergic neurotransmitter system emerging as one of the most notable neurochemical changes, contributing but not limited to emotional and cognitive dysfunction [63].